Granite Investment Partners LLC trimmed its stake in Invuity, Inc. (NASDAQ:IVTY) by 34.3% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 172,635 shares of the medical instruments supplier’s stock after selling 90,032 shares during the period. Granite Investment Partners LLC owned 1.01% of Invuity worth $1,537,000 at the end of the most recent reporting period.
Several other large investors also recently bought and sold shares of IVTY. FMR LLC increased its stake in shares of Invuity by 0.5% in the 1st quarter. FMR LLC now owns 829,564 shares of the medical instruments supplier’s stock worth $6,595,000 after purchasing an additional 4,264 shares in the last quarter. UBS Group AG boosted its holdings in Invuity by 53.4% in the 1st quarter. UBS Group AG now owns 13,200 shares of the medical instruments supplier’s stock worth $105,000 after buying an additional 4,594 shares during the period. Renaissance Technologies LLC bought a new position in Invuity in the 1st quarter worth $151,000. Boston Advisors LLC boosted its holdings in Invuity by 55.6% in the 2nd quarter. Boston Advisors LLC now owns 28,280 shares of the medical instruments supplier’s stock worth $205,000 after buying an additional 10,111 shares during the period. Finally, Spark Investment Management LLC bought a new position in Invuity in the 2nd quarter worth $158,000. Hedge funds and other institutional investors own 69.06% of the company’s stock.
Invuity, Inc. (NASDAQ IVTY) traded down $0.30 on Thursday, hitting $7.10. 76,306 shares of the company’s stock traded hands, compared to its average volume of 113,710. Invuity, Inc. has a twelve month low of $5.70 and a twelve month high of $9.70. The company has a quick ratio of 2.47, a current ratio of 2.90 and a debt-to-equity ratio of 5.39.
Invuity (NASDAQ:IVTY) last announced its earnings results on Tuesday, November 7th. The medical instruments supplier reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.04. The firm had revenue of $9.60 million for the quarter, compared to analysts’ expectations of $9.87 million. Invuity had a negative net margin of 111.43% and a negative return on equity of 212.38%. sell-side analysts forecast that Invuity, Inc. will post -2.41 EPS for the current fiscal year.
Several research analysts recently weighed in on the stock. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $12.00 target price on shares of Invuity in a report on Friday, November 10th. Zacks Investment Research raised shares of Invuity from a “sell” rating to a “hold” rating in a report on Wednesday, October 4th. Northland Securities reaffirmed a “buy” rating and issued a $13.00 target price on shares of Invuity in a report on Tuesday, September 26th. Finally, ValuEngine raised shares of Invuity from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $11.67.
Invuity Company Profile
Invuity, Inc, a medical technology company, develops various surgical devices to address various surgical procedures in the United States. The company integrates its intelligent photonics technology platform into its single-use and reusable advanced surgical devices to address various critical intracavity illumination and visualization challenges.
Receive News & Ratings for Invuity Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invuity Inc. and related companies with MarketBeat.com's FREE daily email newsletter.